Research publications | Alfred Health

Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells

Teh CE, Gong JN, Segal D, Tan T, Vandenberg CJ, Fedele PL, Low MSY, Grigoriadis G, Harrison SJ, Strasser A, Roberts AW, Huang DCS, Nolan GP, Gray DHD, Ko ME

(2020), Cell Death Differ, 27(7), 2217-33

DOI: 10.1038/s41418-020-0498-z

Quality audit of the guidelines for the use of RhD immunoglobulin in obstetrics: Are we getting it right?

Glazebrook B, Akers C, Bielby L, Bastin K, Von Wielligh K, Daly J

(2020), AUST NZ J OBSTET GYN, 60(4), 504-8

DOI: 10.1111/ajo.13177

Treatment practice and outcomes in FLT3-mutant acute myeloid leukemia in the pre-midostaurin era: a real-world experience from Australian tertiary hospitals

Chua CC, Grigg A, Singh J, Droogleever MP, Zhang L, Lim A, Fong CY, Ting SB, Schwarer A, Tiong IS, Wei AH

(2020), LEUKEMIA LYMPHOMA, 61(4), 848-54

DOI: 10.1080/10428194.2019.1691192

Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial

Voso MT, Larson RA, Jones D, Marcucci G, Prior T, Krauter J, Heuser M, Lavorgna S, Nomdedeu J, Geyer SM, Walker A, Wei AH, Sierra J, Sanz MA, Brandwein JM, de Witte TM, Jansen JH, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Amadori S, Cheng Y, Chen Y, Pallaud C, Du L, Piciocchi A, Ehninger G, Byrd J, Thiede C, Döhner K, Stone RM, Döhner H, Bloomfield CD, Lo-Coco F

(2020), Blood Adv, 4(19), 4945-54

DOI: 10.1182/bloodadvances.2020002904

MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia

Montesinos P, Beckermann BM, Catalani O, Esteve J, Gamel K, Konopleva MY, Martinelli G, Monnet A, Papayannidis C, Park A, Récher C, Rodríguez-Veiga R, Röllig C, Vey N, Wei AH, Yoon SS, Fenaux P

(2020), Future Oncol, 16(13), 807-15

DOI: 10.2217/fon-2020-0044

Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

Döhner K, Thiede C, Jahn N, Panina E, Gambietz A, Larson RA, Prior TW, Marcucci G, Jones D, Krauter J, Heuser M, Voso MT, Ottone T, Nomdedeu JF, Mandrekar SJ, Klisovic RB, Wei AH, Sierra J, Sanz MA, Brandwein JM, de Witte T, Jansen JH, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Gathmann I, Benner A, Pallaud C, Stone RM, Döhner H, Bloomfield CD

(2020), Blood, 135(5), 371-80

DOI: 10.1182/blood.2019002697

New directions for emerging therapies in acute myeloid leukemia: the next chapter

Daver N, Wei AH, Pollyea DA, Fathi AT, Vyas P, DiNardo CD

(2020), Blood Cancer J, 10(10), 107

DOI: 10.1038/s41408-020-00376-1

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

Zeidan AM, Boddu PC, Patnaik MM, Bewersdorf JP, Stahl M, Rampal RK, Shallis R, Steensma DP, Savona MR, Sekeres MA, Roboz GJ, DeAngelo DJ, Schuh AC, Padron E, Zeidner JF, Walter RB, Onida F, Fathi A, DeZern A, Hobbs G, Stein EM, Vyas P, Wei AH, Bowen DT, Montesinos P, Griffiths EA, Verma AK, Keyzner A, Bar-Natan M, Navada SC, Kremyanskaya M, Goldberg AD, Al-Kali A, Heaney ML, Nazha A, Salman H, Luger S, Pratz KW, Konig H, Komrokji R, Deininger M, Cirici BX, Bhatt VR, Silverman LR, Erba HP, Fenaux P, Platzbecker U, Santini V, Wang ES, Tallman MS, Stone RM, Mascarenhas J

(2020), Lancet Haematol, 7(8), e601-12

DOI: 10.1016/S2352-3026(20)30205-2

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

Wei AH, Döhner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, Ravandi F, Sayar H, Jang JH, Porkka K, Selleslag D, Sandhu I, Turgut M, Giai V, Ofran Y, Kizil Çakar M, Botelho de Sousa A, Rybka J, Frairia C, Borin L, Beltrami G, Čermák J, Ossenkoppele GJ, La Torre I, Skikne B, Kumar K, Dong Q, Beach CL, Roboz GJ; QUAZAR AML-001 Trial Investigators

(2020), NEW ENGL J MED, 383(26), 2526-37

DOI: 10.1056/NEJMoa2004444

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P

(2020), Blood, 135(24), 2137-45

DOI: 10.1182/blood.2020004856

How I treat acute myeloid leukemia in the era of new drugs

DiNardo CD, Wei AH

(2020), Blood, 135(2), 85-96

DOI: 10.1182/blood.2019001239

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW

(2020), NEW ENGL J MED, 383(7), 617-29

DOI: 10.1056/NEJMoa2012971

notuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemia

Ryland GL, Barraclough A, Fong CY, Fleming S, Bajel A, Hofmann O, Westerman D, Grimmond S, Blombery P

(2020), Brit J Haematol, 191(1), 123-6

DOI: 10.1111/bjh.16949

Cotargeting BCL-2 and MCL-1 in high-risk B-ALL

Moujalled DM, Hanna DT, Hediyeh-Zadeh S, Pomilio G, Brown L, Litalien V, Bartolo R, Fleming S, Chanrion M, Banquet S, Maragno AL, Kraus-Berthier L, Schoumacher M, Mullighan CG, Georgiou A, White CA, Lessene G, Huang DCS, Roberts AW, Geneste O, Rasmussen L, Davis MJ, Ekert PG, Wei A, Ng AP, Khaw SL

(2020), Blood Adv, 4(12), 2762-7

DOI: 10.1182/bloodadvances.2019001416

Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup

Chelle P, Yeung CHT, Croteau SE, Lissick J, Balasa V, Ashburner C, Park YS, Bonanad S, Megías-Vericat JE, Nagao A, Wynn T, Corrales-Medina F, Tran H, Sharathkumar A, Chitlur M, Sarmiento S, Edginton A, Iorio A

(2020), Clin Pharmacokinet, 59(2), 245-56

DOI: 10.1007/s40262-019-00809-6

The Australian experience with switching to extended half-life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation

Brennan Y, Parikh S, McRae S, Tran H

(2020), Haemophilia, 26(3), 529-35

DOI: 10.1111/hae.13970

Incidence of residual perfusion defects by lung scintigraphy in patients treated with rivaroxaban compared with warfarin for acute pulmonary embolism

Lim MS, Nandurkar D, Jong I, Cummins A, Tran H, Chunilal S

(2020), J THROMB THROMBOLYS, 49(2), 220-7

DOI: 10.1007/s11239-019-01944-4

Risk Stratification of Acute Pulmonary Embolism and Determining the Effect on Chronic Cardiopulmonary Complications: The REACH Study

Stevens H, Fang W, Clements W, Bloom J, McFadyen J, Tran H

(2020), TH Open, 40(1), e45-50

DOI: 10.1055/s-0040-1708558

Ischaemic stroke and transient ischaemic attack on anticoagulants: outcomes in the era of direct oral anticoagulants

Valente M, Leung S, Wu P, Oh DH, Tran H, Choi PMC

(2020), Intern Med J, 50(1), 110-3

DOI: 10.1111/imj.14652

Predicting the Risk of Recurrent Venous Thromboembolism: Current Challenges and Future Opportunities

Stevens H, Peter K, Tran H, McFadyen J

(2020), J Clin Med, 9(5), 1582

DOI: 10.3390/jcm9051582